Patents by Inventor Shousun Chen Szu
Shousun Chen Szu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9173932Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: June 2, 2014Date of Patent: November 3, 2015Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Patent number: 8852605Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: April 3, 2007Date of Patent: October 7, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Publication number: 20140287476Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: ApplicationFiled: June 2, 2014Publication date: September 25, 2014Inventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Patent number: 8202520Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: May 28, 2010Date of Patent: June 19, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Patent number: 8168195Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-DGalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: May 22, 2009Date of Patent: May 1, 2012Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Edward Konadu, Yvonne Ageyman Konadu, legal representative
-
Publication number: 20100239601Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: ApplicationFiled: May 28, 2010Publication date: September 23, 2010Inventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Patent number: 7754227Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: March 20, 2007Date of Patent: July 13, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Publication number: 20090232840Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-DGalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: ApplicationFiled: May 22, 2009Publication date: September 17, 2009Inventors: Shousun Chen Szu, John B. Robbins, Edward Konadu, Yvonne Ageyman Konadu
-
Patent number: 7553490Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-DGalpNAc-(1?2)-?-D-PerpNAc-(1?3) -?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: November 12, 2004Date of Patent: June 30, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, legal representative, Edward Konadu
-
Patent number: 7527797Abstract: The invention pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present invention also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: September 1, 2000Date of Patent: May 5, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Patent number: 7247307Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-DGalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: December 16, 2004Date of Patent: July 24, 2007Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Edward Konadu, deceased, Yvonne Ageyman Konadu, legal representative
-
Patent number: 6858211Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-D-GalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.Type: GrantFiled: July 20, 1998Date of Patent: February 22, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, Edward Konadu
-
Publication number: 20040223973Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: ApplicationFiled: June 10, 2004Publication date: November 11, 2004Applicant: The Gov. of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Patent number: 6797275Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: September 1, 2000Date of Patent: September 28, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins
-
Patent number: 5738855Abstract: The present invention is a modified plant, fruit or synthetic oligo- or polysaccharide which has been structurally altered so as to render the modified saccharide antigenically similar to the Vi of Salmonella typhi. The modified saccharide may be conjugated to a carrier to form a conjugate that is immunogenic against S. typhi. Antibodies produced in response to the immunogenic conjugate are protective against typhoid fever. Methods are provided for making the modified saccharide and the immunogenic conjugate.Type: GrantFiled: October 17, 1994Date of Patent: April 14, 1998Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Slavomir Bystricky